These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 22399111)

  • 1. [Botulinum toxin versus sacral neuromodulation for idiopathic detrusor overactivity].
    Leicht W; Hampel C; Thüroff J
    Urologe A; 2012 Mar; 51(3):348-51. PubMed ID: 22399111
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Second-line therapy of idiopathic detrusor overactivity. Sacral neuromodulation and botulinum toxin A].
    Amend B; Castro-Diaz D; Chartier-Kastler E; De Ridder D; Everaert K; Spinelli M; van Kereebroeck P; Sievert KD
    Urologe A; 2010 Feb; 49(2):245-52. PubMed ID: 19859688
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sacral neuromodulation in patients with idiopathic overactive bladder after initial botulinum toxin therapy.
    Smits MA; Oerlemans D; Marcelissen TA; Van Kerrebroeck PE; De Wachter SG
    J Urol; 2013 Dec; 190(6):2148-52. PubMed ID: 23872028
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Standard pharmacological treatment and new therapies for overactive bladder].
    Del Popolo G; Mencarini M; Li Marzi V
    Urologia; 2012; 79(1):6-13. PubMed ID: 22344568
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Neuromodulation as a treatment for overactive bladder syndrome].
    Smits MA; Marcelissen TA; van Kerrebroeck PE; de Wachter SG
    Ned Tijdschr Geneeskd; 2012; 156(33):A4135. PubMed ID: 22894803
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The second-line management of idiopathic overactive bladder: what is the place of sacral neuromodulation and botulinum toxin-A in contemporary practice?
    Chapple C; De Ridder D
    BJU Int; 2009 Nov; 104(9):1188-90. PubMed ID: 19681899
    [No Abstract]   [Full Text] [Related]  

  • 7. [Sacral neuromodulation in urology. The emperor's new clothes or effective high-tech medicine?].
    Hoda MR; Fornara P
    Urologe A; 2010 Oct; 49(10):1254-9. PubMed ID: 20859609
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Urethral instability and sacral nerve stimulation-a better parameter to predict efficacy?
    Groenendijk PM; Heesakkers JP; Lycklama A Nijeholt AA
    J Urol; 2007 Aug; 178(2):568-72; discussion 572. PubMed ID: 17570438
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discontinuation rates and inter-injection interval for repeated intravesical botulinum toxin type A injections for detrusor overactivity.
    Veeratterapillay R; Harding C; Teo L; Vasdev N; Abroaf A; Dorkin TJ; Pickard RS; Hasan T; Thorpe AC
    Int J Urol; 2014 Feb; 21(2):175-8. PubMed ID: 23819724
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preliminary results of botulinum toxin A switch after first detrusor injection failure as a treatment of neurogenic detrusor overactivity.
    Peyronnet B; Roumiguié M; Castel-Lacanal E; Guillotreau J; Malavaud B; Marque P; Rischmann P; Gamé X
    Neurourol Urodyn; 2016 Feb; 35(2):267-70. PubMed ID: 25524826
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Refractory overactive bladder patients who chose sacral neuromodulation therapy after failed OnabotulinumtoxinA treatment: A systematic review and meta-analysis.
    Yang G; Xu Y; Qu G; Zhang Y
    PLoS One; 2020; 15(3):e0230355. PubMed ID: 32226049
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Do Patients Discontinue Overactive Bladder Medications after Sacral Neuromodulation?
    Amin K; Moskowitz D; Kobashi KC; Lee UJ; Lucioni A
    J Urol; 2019 May; 201(5):973-978. PubMed ID: 30694936
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness of BTX-A and neuromodulation in treating OAB with or without detrusor overactivity: a systematic review.
    Rachaneni S; Latthe P
    Int Urogynecol J; 2017 Jun; 28(6):805-816. PubMed ID: 28083714
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Therapy-refractory overactive bladder: alternative treatment approaches].
    Knüpfer S; Hamann M; Naumann CM; Melchior D; Jünemann KP
    Urologe A; 2011 Jul; 50(7):806-9. PubMed ID: 21725649
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Animal models of sacral neuromodulation for detrusor overactivity.
    Vignes JR; Deloire M; Petry K
    Neurourol Urodyn; 2009; 28(1):8-12. PubMed ID: 18785181
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Five-Year Followup Results of a Prospective, Multicenter Study of Patients with Overactive Bladder Treated with Sacral Neuromodulation.
    Siegel S; Noblett K; Mangel J; Bennett J; Griebling TL; Sutherland SE; Bird ET; Comiter C; Culkin D; Zylstra S; Kan F; Berg KC
    J Urol; 2018 Jan; 199(1):229-236. PubMed ID: 28709886
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Re: is on-demand sacral neuromodulation in patients with OAB syndrome a feasible therapy regime?
    Wein AJ
    J Urol; 2013 Feb; 189(2):610-1. PubMed ID: 23312179
    [No Abstract]   [Full Text] [Related]  

  • 18. What is the exact working mechanism of botulinum toxin A and sacral nerve stimulation in the treatment of overactive bladder/detrusor overactivity? ICI-RS 2017.
    Malde S; Fry C; Schurch B; Marcelissen T; Averbeck M; Digesu A; Sahai A
    Neurourol Urodyn; 2018 Jun; 37(S4):S108-S116. PubMed ID: 30133790
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Treatment for refractory non-neurogenic overactive bladder].
    Gamé X; Phé V
    Prog Urol; 2020 Nov; 30(14):920-930. PubMed ID: 33220820
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current information on sacral neuromodulation and botulinum toxin treatment for refractory idiopathic overactive bladder syndrome: a review.
    Leong RK; De Wachter SG; van Kerrebroeck PE
    Urol Int; 2010; 84(3):245-53. PubMed ID: 20389150
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.